新型肝癌标志物的临床应用研究进展  

Advances in clinical application of novel liver cancer markers

作　　者：张丽芳 袁野[1] 史林[1,2] 张德太 ZHANG Lifang;YUAN Ye;SHI Lin

机构地区：[1]华中科技大学同济医学院附属协和医院组织工程与再生医学研究中心,武汉430022 [2]华中科技大学同济医学院附属协和医院检验科

出　　处：《临床血液学杂志》2022年第4期297-302,共6页Journal of Clinical Hematology

摘　　要：1概述根据GLOBOCAN 2020的报道,2020年全球有905677例肝癌新发和830180例死亡患者[1]。原发性肝癌在我国年新发46.6万例,死亡42.2万例,在恶性肿瘤发病率中排名第4,肿瘤致死病因排名第2[2]。常见的肝癌有肝细胞癌(hepatocellular carcinoma,HCC)和肝内胆管癌(intrahepatic cholangiocarcinoma,ICC),分别占75%~85%和10%~15%[1]。肝癌的筛查和临床诊断首先依靠影像学检查及AFP等肿瘤标志物,必要时可以采取肝穿刺活检明确诊断,见图1[2]。Primary liver cancer is the most common type of malignant tumors in China. Due to the insufficient early diagnosis, most of the patients with liver cancer are diagnosed in the advanced stages, resulting in poor prognosis. Currently, the diagnostic methods for liver cancer are dependent on the traditional biomarkers alpha-fetoprotein(AFP), together with ultrasound and other imaging techniques. However, the sensitivity and specificity of these biomarkers are not optimal. Noninvasive, serum-based biomarkers are urgently required for the early detection of HCC.This review briefly describes the progresses in the potential biomarkers for HCC diagnosis.

关 键 词：肝癌 生物标志物 研究进展 

分 类 号：R735.7[医药卫生—肿瘤]